Treatment of persistent lung infections in CF patients will remain important even as CFTR modulating therapies become more commonplace, as this treatment strategy appears to have a limited effect on bacterial clearance in patients with low microbial diversity (7). The gene discussed is CFTR; the disease is cystic fibrosis.